Inhibition of in vitro protein synthesis by a carbocyclic puromycin analog.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D001426:Bacterial Proteins / Q000096:biosynthesis*; D002247:Carbon Isotopes; D002277:Carcinoma / Q000188:drug therapy; D002460:Cell Line; D002701:Chloramphenicol / Q000494:pharmacology; D003597:Cytosine Nucleotides / Q000494:pharmacology; D003864:Depression, Chemical; D004926:Escherichia coli / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D007938:Leukemia / Q000188:drug therapy; D007939:Leukemia L1210 / Q000188:drug therapy; D009062:Mouth Neoplasms / Q000188:drug therapy; D010452:Peptide Biosynthesis; D010649:Phenylalanine / Q000378:metabolism; D011119:Polynucleotides / Q000494:pharmacology; D011691:Puromycin / Q000494:pharmacology* / Q000627:therapeutic use; D012270:Ribosomes / Q000187:drug effects / Q000378:metabolism; D013237:Stereoisomerism; D014500:Uracil Nucleotides / Q000494:pharmacology
D000970:Antineoplastic Agents; D001426:Bacterial Proteins; D002247:Carbon Isotopes; D003597:Cytosine Nucleotides; D011119:Polynucleotides; D014500:Uracil Nucleotides; D010649:Phenylalanine; D011691:Puromycin; D002701:Chloramphenicol